Soros Fund Management’s Edwards Lifesciences EW Stock Holding History

Soros Fund Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-250,000	Closed	-$18.5M	–	228
2024 Q4	$18.5M	Sell	250,000 -50,000	-17%	-$3.5M	0.28%	93
2024 Q3	$19.8M	Buy	+300,000	New	+$21.8M	0.29%	79
2024 Q2	–	Sell	-75,000	Closed	-$7.17M	–	190
2024 Q1	$7.17M	Buy	+75,000	New	+$6.3M	0.12%	130
2017 Q3	–	Sell	-13,800	Closed	-$544K	–	243
2017 Q2	$544K	Buy	+13,800	New	+$504K	0.01%	127

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Soros Fund Management's EW Position: Q1 2025 in Review

Soros Fund Management sold out of Edwards Lifesciences (EW) in Q1 2025, closing a stake of 250,000 shares — an estimated $18.5M sold.

Soros Fund Management first reported a position in EW in Q2 2017 and held it in 4 quarters. The position peaked at $19.8M in Q3 2024. 1,207 funds tracked by Wall St. Rank hold EW as of Q1 2025.

Soros Fund Management reported no remaining Edwards Lifesciences position as of Q1 2025 after selling out during the quarter.
Soros Fund Management sold 250,000 Edwards Lifesciences shares in Q1 2025, an estimated $18.5M.
Soros Fund Management first reported a position in Edwards Lifesciences in Q2 2017 and held it in 4 quarters.
Soros Fund Management's Edwards Lifesciences position peaked at $19.8M in Q3 2024.
1,207 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2025.

Based on Soros Fund Management's 13F filing for Q1 2025, filed 15 May 2025.